- DL-O-Phosphoserine
-
- $41.00 / 500mg
-
2026-01-07
- CAS:17885-08-4
- Min. Order:
- Purity: 99.83%
- Supply Ability: 10g
- DL-O-Phosphoserine
-
- $0.00 / 1KG
-
2026-01-07
- CAS:17885-08-4
- Min. Order: 1KG
- Purity: 98%min
- Supply Ability: 30tons/month
- DL-O-Phosphoserine
-
- $0.00 / 1KG
-
2026-01-07
- CAS:17885-08-4
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 20TONS
|
| | DL-O-Phosphoserine Basic information |
| | DL-O-Phosphoserine Chemical Properties |
| Melting point | 190 °C(lit.) | | Boiling point | 475.4±55.0 °C(Predicted) | | density | 1.809 | | storage temp. | -15°C | | solubility | H2O: 50 mg/mL hot, clear, colorless to slightly yellow | | form | Solid | | pka | 1.71±0.10(Predicted) | | color | White to Off-White | | Merck | 7363 | | BRN | 1726828 | | InChI | InChI=1S/C3H8NO6P/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1 | | InChIKey | BZQFBWGGLXLEPQ-REOHCLBHSA-N | | SMILES | C(O)(=O)[C@H](COP(O)(O)=O)N | | CAS DataBase Reference | 17885-08-4(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | F | 10 |
| | DL-O-Phosphoserine Usage And Synthesis |
| Chemical Properties | White to faint beige crystalline powder | | Uses | DL-O-Phosphoserine is used in alternative pathways for biosynthesis of cysteine and of selenocysteine. | | Definition | ChEBI: A serine derivative that is serine substituted at the oxygen atom by a phosphono group. | | Biochem/physiol Actions | O-Phospho-DL-serine (pSer) is used in the study of non-enzymatic aminophospholipid glycation. | | in vivo | O-phospho-L-serin can be used in retinal research to explore the regulatory mechanism of Müller glial cell proliferation and photoreceptor regeneration; in bone repair research, to evaluate the effects on bone cement performance and bone healing; in insect research, to identify the role of D-serine in insect growth and development. In the zebrafish light-damaged retinal model experiment, O-phospho-L-serin (20 mM, 0.5 μL; iv; injected before light treatment; single dose) can significantly reduce the number of proliferating cell nuclear antigen (PCNA)-positive Müller glial cells 51 hours after light damage, and inhibit the regeneration of cones in the light-damaged retina, but has no significant effect on the number of light-induced photoreceptor cell death[1].
In a miniature pig mandibular bone defect model experiment, a modified bone cement prepared by surgical implantation of a mixture of O-phospho-L-serin (Biozement D (2 g)-collagen-I (2.5%)-phosphoserine (50 mg)) was administered. Compared with the unmodified bone cement, the treated group had a higher absorption rate and bone regeneration rate, which effectively promoted bone healing[2].
In a silkworm growth and development experiment, O-phospho-L-serin (20 mM, 1 mL; added to feed; daily administration, from first to fifth instar larvae) delayed the development of silkworm larvae by about 6 days, significantly reduced the survival rate of larvae, and reduced the D-serine level in larvae until the cocooning stage compared with the control group[3]. | Animal Model: | Zebrafish retinal light damage model[1] | | Dosage: | 0.65% saline containing either 20 mM O-phospho-L-serine (L-SOP), 0.5 μL | | Administration: | Intravitreally injection via Hamilton syringe; single dose | | Result: | Decreased the number of PCNA-positive Müller glia 51 hours after light damage.
Inhibited the regeneration of cone photoreceptors in the light-damaged retina.
There was no significant difference in the number of light-induced photoreceptor cell deaths between the O-phospho-L-serin-injected group and the control group 24 hours after light treatment. |
| | IC 50 | Human Endogenous Metabolite |
| | DL-O-Phosphoserine Preparation Products And Raw materials |
|